clobetasol and Mouth-Diseases

Despite the common prevalence of cutaneous psoriasis, the existence of manifestations in the oral cavity is subject to controversy. In this article, dermatologic psoriasis is reviewed, and a patient with generalized, symptomatic oral mucosal erythema resembling atrophic candidiasis synchronous with flare of chronic skin psoriasis is described. Diagnostic work up and therapeutic response supported that these mucosal findings were the oral counterpart of cutaneous disease. Dental providers should be familiar with the signs and symptoms of oral psoriasis, institute appropriate preventive measures, and provide palliation directed at symptomatic oral changes of psoriasis.

Topics: Aged; Anti-Inflammatory Agents; Clobetasol; Diagnosis, Differential; Female; Humans; Mouth Diseases; Psoriasis

Lichen sclerosus et atrophicus is a depigmenting mucocutaneous disease most frequently affecting the female genitalia. Genital lesions are symptomatic and may be functionally debilitating. Oral lesions are of little significance other than the esthetic concerns of perioral lesions. In view of the rarity of reported cases, one lesion of the labial mucocutaneous area and a second of the palate are presented along with a description of the disease's clinical and histopathologic findings and a brief review of the literature. The lip lesion was partially resolved with topical corticosteroids and was then fully eliminated with topical testosterone. Histologic verification and examination for the simultaneous occurrence or absence of oral and the more common genital-cutaneous lesions is essential if meaningful information in the medical-dental literature is to be obtained in the future.

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Clobetasol; Diagnosis, Differential; Glucocorticoids; Humans; Lichen Planus, Oral; Lichen Sclerosus et Atrophicus; Lip Diseases; Male; Mouth Diseases; Palate, Soft; Testosterone

Patients who undergo allogeneic stem cell transplantation frequently develop an immunologic disease caused by the reactivation of the graft to the host tissues. This disease is called graft-versus-host disease (GVHD) and it is usually a systemic disorder. In a large proportion of cases, oral disorders that are related to a chronic phase of GVHD (cGVHD) occur, and their treatment involves the use of topical immunosuppressive drugs. Several medications have been studied for this purpose, but only a small number of clinical trials have been published. The present study is a randomized, double-blind clinical trial that compares topical clobetasol and dexamethasone for the treatment of symptomatic oral cGVHD. Patients were randomly assigned to treatment with clobetasol propionate .05% or dexamethasone .1 mg/mL for 28 days. In both arms, nystatin 100,000 IU/mL was administered with the corticosteroid. Oral lesions were evaluated by the modified oral mucositis rating scale (mOMRS) and symptoms were registered using a visual analogue scale. Thirty-five patients were recruited, and 32 patients were randomized into the study groups: 18 patients (56.3%) to the dexamethasone group and 14 patients (43.8%) to the clobetasol group. The use of clobetasol resulted in a significant reduction in mOMRS total score (P = .04) and in the score for ulcers (P = .03). In both groups, there was significant symptomatic improvement but the response was significantly greater in the clobetasol group (P = .02). In conclusion, clobetasol was significantly more effective than dexamethasone for the amelioration of symptoms and clinical aspects of oral lesions in cGVHD.

Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents; Clobetasol; Dexamethasone; Double-Blind Method; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Mouth Diseases; Transplantation Conditioning; Transplantation, Homologous

Clobetasol is the most potent topical corticosteroid used in oral medicine for muco-cutaneous diseases. Several papers reported about patients with cushingoid appearance, suggesting an adrenal suppression related to clobetasol systemic absorption after local application. Owing to the lack of studies, our goal is to assess whether transmucosal assimilation, after its application on oral mucosa, really occurs and to define clobetasol pharmacokinetics profile.. Data were recorded by collecting blood samples both on 10 patients in clobetasol therapy and on 14 healthy volunteers instructed about standardized clobetasol applications. A new technique of analytical chemistry was employed to detect its serum concentrations.. Clobetasol absorption was ascertained, showing a certain accumulation rate. Different levels have been found in relation to oral disease and individual features (as smoking habits and presence of oral mucosa erosion).. Our study validates clobetasol systemic transmucosal absorption, also recommending a careful monitoring of patients in corticosteroid therapy to avoid local and systemic adverse effects.

Topics: Absorption; Administration, Buccal; Aged; Anti-Inflammatory Agents; Chromatography, High Pressure Liquid; Clobetasol; Cross-Sectional Studies; Female; Glucocorticoids; Humans; Lichen Planus, Oral; Male; Mouth Diseases; Mouth Mucosa; Pemphigoid, Benign Mucous Membrane; Smoking; Tandem Mass Spectrometry; Young Adult

Because of their chronic nature treatment of oral vesiculoerosive diseases remains a challenge to the oral medicine specialist. Even though oral vesiculoerosive diseases respond well to systemic steroids, adverse side effects sometimes limit their use. Potent topical steroids are becoming increasingly useful to treat these chronic conditions with good control. The purpose of this double-blind clinical trial was to compare clobetasol propionate and fluocinonide ointment in orabase as treatments for controlling oral vesiculoerosive diseases. Sixty patients were asked to participate (43 women and 17 men). Data are reported for 55 patients. Each patient was seen at baseline and at days 7, 14, 21, and 28. Variables evaluated were pain, erythema, atrophy, and size of lesion. Overall, both medications had a beneficial effect in the control of symptoms and signs of oral vesiculoerosive diseases with minimal side effects. Clobetasol propionate was better than fluocinonide as measured by more rapid control of pain (within 7 days). Candidiasis was observed in 13 patients at the end of treatment (most of them carriers of Candida). Therefore normal carriers should be identified and treatment with antifungal therapy instituted before the patient begins using topical steroids.

Topics: Aged; Carboxymethylcellulose Sodium; Clobetasol; Double-Blind Method; Erythema Multiforme; Female; Fluocinonide; Humans; Lichen Planus, Oral; Linear Models; Male; Middle Aged; Mouth Diseases; Pemphigoid, Benign Mucous Membrane; Pemphigus

Clobetasol propionate (Temovate), a novel high-potency topical corticosteroid, was used in open trial from 1987 to 1988 on 24 patients with persistent oral vesiculoerosive disease of at least 1 month's duration. Fourteen women and 10 men, ranging in age from 27 to 76 years (mean 48 years), participated. Nine patients had erosive lichen planus, one had benign mucous membrane pemphigoid, three had pemphigus vulgaris, seven had persistent major recurrent aphthous stomatitis, and four had chronic oral erythema multiforme. Fifteen patients had complete remission of signs and symptoms, seven had excellent response of signs and complete remission of symptoms, and two failed to respond. All other topical therapy was suspended before and during the study. All patients responded to two or three applications daily of medication. Side effects were minor and reversible, and included localized candidiasis (three patients), stomatopyrosis (two), and hypogeusia (one). Clobetasol propionate ointment in adhesive paste (Orabase) thus seems to be an effective topical steroid alternative to other less potent topical and systemic drugs for recalcitrant oral vesiculoerosive disease.

Topics: Adult; Aged; Clobetasol; Female; Humans; Hydrocortisone; Lichen Planus; Male; Middle Aged; Mouth Diseases; Pemphigoid, Benign Mucous Membrane; Pemphigus; Stomatitis, Aphthous

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Diagnosis, Differential; Female; Humans; Mouth Diseases; Pemphigus; Pregnancy; Pregnancy Complications; Prenatal Diagnosis

Oral lichen planus is a common, chronic mucosal disease associated with T-cell-mediated immunological dysfunction. The disease is classified in a painful red form with erosions and ulcerations and a less painful to painless white form with reticular, papular and plaque lesions. In a small proportion of cases, the lesions may develop into a squamous cell carcinoma. Corticosteroids are the mainstay of the therapy; the combination of systemic and topical corticosteroids is often very effective. Topical calcineurin inhibitors, especially tacrolimus, have produced long-term responses in clinical studies. We describe a patient with excellent response to therapy with tacrolimus mouthrinse and systemic corticosteroids.

Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Clobetasol; Drug Therapy, Combination; Humans; Injections, Intravenous; Lichen Planus, Oral; Male; Middle Aged; Mouth Diseases; Tacrolimus; Treatment Outcome

The authors present a case demonstrating the success of topical tacrolimus (TAC) therapy with custom trays in the treatment of oral chronic graft-versus-host disease (cGVHD). The 41-year-old male patient initially responded to topical steroid therapy (clobetasol propionate 0.05% ointment) applied both topically and with flexible carrier trays, but later became refractory to this potent topical agent. Topical TAC therapy with flexible carrier trays and systemic prednisone therapy was initiated.. The patient responded favorably with the change to topical TAC therapy with custom trays (and oral prednisone). His oral cGVHD lesions resolved within a period of 4 weeks. The improvement has remained stable at 14 months of follow-up.. This is the first case reported with regard to the successful resolution of steroid recalcitrant cGVHD successfully treated with topical TAC with custom trays.

Topics: Administration, Topical; Adult; Clobetasol; Drug Carriers; Follow-Up Studies; Glucocorticoids; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Mouth Diseases; Myelodysplastic Syndromes; Recurrence; Tacrolimus

Topics: Administration, Topical; Adult; Clobetasol; Female; Follow-Up Studies; Glucocorticoids; Humans; Mouth Diseases; Mouth Mucosa; Mucocele; Patch Tests; Recurrence

Orofacial granulomatosis (OFG) is a descriptive term used for granulomatous disorders of the face and oral cavity that may occur for a variety of reasons, some of which result in significant morbidity and mortality. Although rarely, a granular enlargements of the gingiva may be the first clinical manifestation of OFG, preceding other local or systemic manifestations.. We will report a case of OFG that showed an atypical and monosymptomatic onset with a generalized hyperplastic gingivitis that preceded other facial and mucosal features by several weeks.. Considering the variable clinical onset of OFG and its apparent increase in incidence, we emphasize that in some cases, the periodontologist, as first consulted health care professional, plays an important role to detect this disorder. Early diagnosis of OFG is a crucial step to prevent and cure its unsightly sequelae and sometimes avoid progression of systemic potentially life-threatening OFG-related diseases.. Thus, when none of the common causes of gingival enlargement can be detected, OFG diagnosis should be suspected.

Topics: Adult; Anti-Inflammatory Agents; Cheilitis; Clobetasol; Diagnosis, Differential; Disease Progression; Edema; Face; Female; Giant Cells; Gingival Hyperplasia; Glucocorticoids; Granuloma; Humans; Mouth Diseases; Triamcinolone

In the present study the efficacy of systemic and topical steroid treatment in the management of 11 patients with mucous membrane pemphigoid (MMP) confirmed histologically and immunologically has been evaluated. Eight patients were treated with a topically applied clobetasol in a bioadhesive gel (2-3 times/daily) and with chlorexidine mouth-washes (3 times/daily) and myconazole gel (1 time/daily) as antimycotics. The remaining 3 were treated with systemic prednisone (25 to 100 mg/daily) followed by a topical therapy with clobetasol, chlorexidine and myconazole. In 6 cases (54%), 4 topically treated and 2 systemically plus topically treated, we observed a complete clearance of signs and symptoms of MMP in an average period of 5.7 months. In the remaining 5 cases (46%), 4 topically treated and 1 systemically plus topically treated, we observed partial healing of the oral lesions. One patient treated with a high dose of prednisone (100 mg/daily) showed side-effects (insomnia, fluid retention and gastralgia) whereas other 3 subjects had oral candidiasis. In a mean follow-up time of 13 months (range 6 to 27) 6 patients (54%) were free of disease, 3 (27%) had a marked improvement and 2 (18%) had new active lesions of MMP. These results suggest that often in the treatment of MMP a systemic corticosteroid therapy followed by a treatment with high potency topical steroids is useful to obtain a good control of MMP.

Topics: Administration, Oral; Administration, Topical; Adult; Aged; Chlorhexidine; Clobetasol; Female; Humans; Male; Miconazole; Middle Aged; Mouth Diseases; Mouth Mucosa; Pemphigoid, Benign Mucous Membrane; Prednisone

A case of discoid lupus erythematosus with oral manifestations only is presented. The patient complained of painful palatal ulcers that limited her dietary intake. A topical therapeutic regimen using plastic carriers containing clobetasol propionate was beneficial in significantly relieving the oral discomfort. The clinical and microscopic differential diagnoses for this mucocutaneous disease are also discussed.

Topics: Clobetasol; Female; Humans; Lupus Erythematosus, Discoid; Middle Aged; Mouth Diseases; Mouth Mucosa

The treatment of eight patients with histologically verified atrophic or erosive lichen planus are reported. The lesions of WHO-diagnosis code 697.02 were subdivided into three classes: atrophic, minor erosive and major erosive. Clobetasol Propionate ointment was placed in the buccal mucosa under an occlusive DuodermR dressing. Healing with striation was obtained in all of those lesions classified as atrophic or minor erosive, while major erosive lesions showed improvement, but persisted.

Topics: Aged; Clobetasol; Female; Humans; Lichen Planus; Male; Middle Aged; Mouth Diseases